Kevin McCulloch - 02 Oct 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: President and Chief Operating Officer
Signature: /s/ Beth Hecht, Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 02 Oct 2025
Net transactions value: -$6,091
Form type: 4
Filing time: 03 Oct 2025, 17:21:11 UTC
Previous filing: 15 Sep 2025
Next filing: 09 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
McCulloch Kevin	President and Chief Operating Officer	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	03 Oct 2025	0002031695

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Tax liability	$6,091	-733	-0.04%	$8.31	1,700,426	02 Oct 2025	Direct	F1
holding	XERS	Common Stock						25,000	02 Oct 2025	By Spouse	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of October 2, 2025.
F2	The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer